报价延迟最少15分钟:2026/04/21 20:02 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.9047 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.33/-0.99
|
|
企业价值
54.81M
|
| 资产负债 |
|
每股账面净值
0.51
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
0.51
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics. |
